Vol.27/No.9

Focal therapy for prostate cancer has evolved over 2 decades, with advances in imaging, patient selection, treatment modalities, and clinical trials.

Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.

Maurie Markman, MD, discusses conflicts of interest in cancer care.

In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.

Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.

Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Cancer Disparities Progress Report and what oncologists can do to combat them.

Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.

OncLive spoke with expert investigators to gather insights on the role of AI in cancer care, including oncologic surgery and drug development.

Brian Myre, MD, discusses phase 1 data with the novel in situ SYNC-T Therapy SV-102 and the ongoing phase 2 LEGION-100 study in prostate cancer.